🟢 Generate Biomedicines is trading 5% up in after-hours trading after Zealand Pharma metabolic-disease partnership

Generate Biomedicines is trading at $12.89, up 5.18%, after announcing a Zealand Pharma collaboration to develop AI-designed protein therapeutics for obesity and other metabolic diseases.

• The deal includes $30 million upfront and up to $35 million in early preclinical milestones.
• Potential milestones are nearly $1.2 billion, plus royalties.
• Reuters reported shares were up about 5% in extended trading following the announcement.